{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:12:10Z","timestamp":1789035130598,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01590-z","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:38:52Z","timestamp":1789033132000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Advanced Gastric and Gastroesophageal Junction Cancer: Evidence, Sequencing, Patient Selection, and Clinical Decision-Making"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4795","authenticated-orcid":false,"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"3","key":"1590_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1590_CR2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","volume":"18","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476\u201384. https:\/\/doi.org\/10.1007\/s10120-014-0402-y.","journal-title":"Gastric Cancer"},{"issue":"4","key":"1590_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/PAI.0000000000000423","volume":"26","author":"WH Kim","year":"2018","unstructured":"Kim WH, Gomez-Izquierdo L, Vilardell F, et al. HER2 status in gastric and gastroesophageal junction cancer: results of the large, multinational HER-EAGLE study. Appl Immunohistochem Mol Morphol. 2018;26(4):239\u201345. https:\/\/doi.org\/10.1097\/PAI.0000000000000423.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"9742","key":"1590_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"issue":"10418","key":"1590_CR5","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Yanez P, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197\u2013208. https:\/\/doi.org\/10.1016\/S0140-6736(23)02033-0.","journal-title":"Lancet"},{"issue":"14","key":"1590_CR6","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1056\/NEJMc2408121","volume":"391","author":"YY Janjigian","year":"2024","unstructured":"Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab in HER2-positive gastric cancer. N Engl J Med. 2024;391(14):1360\u20132. https:\/\/doi.org\/10.1056\/NEJMc2408121.","journal-title":"N Engl J Med"},{"issue":"6","key":"1590_CR7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1470-2045(19)30088-9","volume":"20","author":"K Shitara","year":"2019","unstructured":"Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20(6):827\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(19)30088-9.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1590_CR8","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1056\/NEJMoa2503119","volume":"393","author":"K Shitara","year":"2025","unstructured":"Shitara K, Van Cutsem E, G\u00fcm\u00fc\u015f M, et al. Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer. N Engl J Med. 2025;393(4):336\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2503119.","journal-title":"N Engl J Med"},{"issue":"2_suppl","key":"1590_CR9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1200\/JCO.2026.44.2_suppl.434","volume":"44","author":"K Shitara","year":"2026","unstructured":"Shitara K, Van Cutsem E, Shen L, et al. Exploratory analysis of HER2 status based on central and local testing results from the DESTINY-Gastric04 study. J Clin Oncol. 2026;44(2_suppl):434. https:\/\/doi.org\/10.1200\/JCO.2026.44.2_suppl.434.","journal-title":"J Clin Oncol"},{"key":"1590_CR10","doi-asserted-by":"publisher","unstructured":"Shitara K, Bang YJ, Iwasa S, DESTINY-Gastric01 Investigators, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2004413.","DOI":"10.1056\/NEJMoa2004413"},{"issue":"4","key":"1590_CR11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1200\/JCO.22.00575","volume":"41","author":"K Yamaguchi","year":"2023","unstructured":"Yamaguchi K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial. J Clin Oncol. 2023;41(4):816\u201325. https:\/\/doi.org\/10.1200\/JCO.22.00575.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1590_CR12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem E, di Bartolomeo M, Smyth E, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24(7):744\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(23)00215-2.","journal-title":"Lancet Oncol"},{"key":"1590_CR13","doi-asserted-by":"publisher","first-page":"103404","DOI":"10.1016\/j.eclinm.2025.103404","volume":"87","author":"Z Peng","year":"2025","unstructured":"Peng Z, Chen P, Lu J, et al. Trastuzumab deruxtecan in patients from China with previously treated HER2-positive locally advanced\/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trial. EClinicalMedicine. 2025;87:103404. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103404.","journal-title":"EClinicalMedicine"},{"issue":"4","key":"1590_CR14","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","volume":"35","author":"AN Bartley","year":"2017","unstructured":"Bartley AN, Washington MK, Colasacco C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017;35(4):446\u201364. https:\/\/doi.org\/10.1200\/JCO.2016.69.4836.","journal-title":"J Clin Oncol"},{"key":"1590_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2018.09.024","volume":"105","author":"H Saeki","year":"2018","unstructured":"Saeki H, Oki E, Kashiwada T, et al. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). Eur J Cancer. 2018;105:41\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.024.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1590_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10120-018-0891-1","volume":"22","author":"S Seo","year":"2019","unstructured":"Seo S, Ryu MH, Park YS, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer. 2019;22(3):527\u201335. https:\/\/doi.org\/10.1007\/s10120-018-0891-1.","journal-title":"Gastric Cancer"},{"issue":"12","key":"1590_CR17","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1002\/ijc.30408","volume":"139","author":"F Pietrantonio","year":"2016","unstructured":"Pietrantonio F, Caporale M, Morano F, et al. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research. Int J Cancer. 2016;139(12):2859\u201364. https:\/\/doi.org\/10.1002\/ijc.30408.","journal-title":"Int J Cancer"},{"issue":"11","key":"1590_CR18","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1007\/s00535-018-1464-0","volume":"53","author":"T Wakatsuki","year":"2018","unstructured":"Wakatsuki T, Yamamoto N, Sano T, et al. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. J Gastroenterol. 2018;53(11):1186\u201395. https:\/\/doi.org\/10.1007\/s00535-018-1464-0.","journal-title":"J Gastroenterol"},{"key":"1590_CR19","unstructured":"Japanese Gastric Cancer Association Guideline Committee. Overview of the DESTINY-Gastric04 trial and commentary on trastuzumab deruxtecan as second-line treatment for HER2-positive unresectable advanced or recurrent gastric\/gastroesophageal junction cancer [Japanese]. March 24. 2026. Available at: https:\/\/www.jgca.jp\/wp-content\/uploads\/2023\/08\/destiny_202603.pdf. Accessed August 25, 2026."},{"issue":"7","key":"1590_CR20","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","volume":"30","author":"K Shitara","year":"2024","unstructured":"Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. Nat Med. 2024;30(7):1933\u201342. https:\/\/doi.org\/10.1038\/s41591-024-02992-x.","journal-title":"Nat Med"},{"issue":"11","key":"1590_CR21","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, RAINBOW Study Group, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(14)70420-6.","journal-title":"Lancet Oncol"},{"key":"1590_CR22","unstructured":"Pharmaceuticals and Medical Devices Agency. Enhertu for Intravenous Drip Infusion 100\u00a0mg [Japanese electronic package insert]. Revised March 2026. Available at: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/430574_4291452D1029_1_12. Accessed August 25, 2026."},{"key":"1590_CR23","unstructured":"European Medicines Agency. Enhertu: EPAR product information. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enhertu-epar-product-information_en.pdf. Accessed August 25, 2026."},{"issue":"11","key":"1590_CR24","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara K, Doi T, Dvorkin M, et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437\u201348. https:\/\/doi.org\/10.1016\/S1470-2045(18)30739-3.","journal-title":"Lancet Oncol"},{"issue":"10111","key":"1590_CR25","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5.","journal-title":"Lancet"},{"issue":"10","key":"1590_CR26","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol"},{"issue":"5","key":"1590_CR27","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jjco\/hyaf216","volume":"56","author":"Y Narita","year":"2026","unstructured":"Narita Y, Kawakami H, Nakanishi K, et al. Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR study. Jpn J Clin Oncol. 2026;56(5):538\u201345. https:\/\/doi.org\/10.1093\/jjco\/hyaf216.","journal-title":"Jpn J Clin Oncol"},{"key":"1590_CR28","doi-asserted-by":"publisher","unstructured":"Kawakami H, Nakanishi K, Makiyama A, EN-DEAVOR Study Group, et al. Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study). Gastric Cancer. 2025;28(1):51\u201361. https:\/\/doi.org\/10.1007\/s10120-024-01555-w.","DOI":"10.1007\/s10120-024-01555-w"},{"key":"1590_CR29","doi-asserted-by":"publisher","first-page":"100184","DOI":"10.1016\/j.esmogo.2025.100184","volume":"8","author":"K Nakanishi","year":"2025","unstructured":"Nakanishi K, Sugimoto N, Kodera Y, et al. Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study. ESMO Gastrointest Oncol. 2025;8:100184. https:\/\/doi.org\/10.1016\/j.esmogo.2025.100184.","journal-title":"ESMO Gastrointest Oncol"},{"issue":"1","key":"1590_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10120-024-01560-z","volume":"28","author":"A Jubashi","year":"2025","unstructured":"Jubashi A, Nakayama I, Koganemaru S, et al. Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer. Gastric Cancer. 2025;28(1):63\u201373. https:\/\/doi.org\/10.1007\/s10120-024-01560-z.","journal-title":"Gastric Cancer"},{"issue":"12","key":"1590_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105914","volume":"10","author":"H Kawakami","year":"2025","unstructured":"Kawakami H, Uchino K, Hashimoto W, Muro K. Real-world evaluation of interstitial lung disease\/pneumonitis in patients treated with trastuzumab deruxtecan for HER2-positive advanced or recurrent gastric cancer: a postmarketing surveillance study in Japan. ESMO Open. 2025;10(12):105914. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105914.","journal-title":"ESMO Open"},{"issue":"10","key":"1590_CR32","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s40264-023-01328-x","volume":"46","author":"JWY Chiu","year":"2023","unstructured":"Chiu JWY, Lee SC, Ho JCM, et al. Clinical guidance on the monitoring and management of trastuzumab deruxtecan (T-DXd)-related adverse events: insights from an Asia-Pacific multidisciplinary panel. Drug Saf. 2023;46(10):927\u201349. https:\/\/doi.org\/10.1007\/s40264-023-01328-x.","journal-title":"Drug Saf"},{"key":"1590_CR33","unstructured":"Daiichi Sankyo Co., Ltd. Enhertu appropriate use guide [Japanese]. Revised. March 2026. Available at: https:\/\/www.pmda.go.jp\/RMP\/www\/430574\/d0b29598-fe09-4105-a18e-b5ae425a092e\/430574_42914D0D1026_10_011RMPm.pdf. Accessed August 25, 2026."},{"issue":"11","key":"1590_CR34","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.annonc.2025.07.015","volume":"36","author":"HS Rugo","year":"2025","unstructured":"Rugo HS, Tokunaga E, Iwata H, et al. Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease\/pneumonitis. Ann Oncol. 2025;36(11):1389\u201399. https:\/\/doi.org\/10.1016\/j.annonc.2025.07.015.","journal-title":"Ann Oncol"},{"key":"1590_CR35","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1007\/s10147-025-02748-8","volume":"30","author":"T Aoyama","year":"2025","unstructured":"Aoyama T, Ooki A, Oba K, et al. A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced\/recurrent gastric cancer treated with trastuzumab deruxtecan: the EN-hance study. Int J Clin Oncol. 2025;30:1162\u201373. https:\/\/doi.org\/10.1007\/s10147-025-02748-8.","journal-title":"Int J Clin Oncol"},{"issue":"41","key":"1590_CR36","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. Eur Heart J. 2022;43(41):4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"issue":"4","key":"1590_CR37","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1136\/gutjnl-2024-334667","volume":"75","author":"T Sheng","year":"2026","unstructured":"Sheng T, Sundar R, Srivastava S, et al. Spatial profiling of patient-matched HER2-positive gastric cancer reveals resistance mechanisms to targeted therapy. Gut. 2026;75(4):733\u201347. https:\/\/doi.org\/10.1136\/gutjnl-2024-334667.","journal-title":"Gut"},{"key":"1590_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2025.100294","volume":"11","author":"YY Janjigian","year":"2026","unstructured":"Janjigian YY, Smyth E, Shen L, et al. DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer. ESMO Gastrointest Oncol. 2026;11:100294. https:\/\/doi.org\/10.1016\/j.esmogo.2025.100294.","journal-title":"ESMO Gastrointest Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01590-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01590-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01590-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:38:54Z","timestamp":1789033134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01590-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1590"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01590-z","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During preparation and revision of this manuscript, the authors used ChatGPT (OpenAI) to assist with manuscript drafting and revision, language refinement, organization, and consistency checking. All scientific claims, numerical data, references, and final wording were independently reviewed and verified by the authors, who take full responsibility for the content.","order":2,"name":"Ethics","label":"Use of generative AI and AI-assisted technologies","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"217"}}